Display options
Cite
Heitmann JS, Pfluegler M, Jung G, et al. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers (Basel). 2021;13(3)doi: 10.3390/cancers13030549.
Heitmann, J. S., Pfluegler, M., Jung, G., Salih, H. R., & Elpus, K. (2021). Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers, 13(3), . https://doi.org/10.3390/cancers13030549
Heitmann, Jonas S, et al. "Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives." Cancers vol. 13,3 (2021). doi: https://doi.org/10.3390/cancers13030549
Heitmann JS, Pfluegler M, Jung G, Salih HR, Elpus K. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers (Basel). 2021 Feb 01;13(3). doi: 10.3390/cancers13030549. PMID: 33535627; PMCID: PMC7867165.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Feb 01;13(3). doi: 10.3390/cancers13030549.

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives.

Cancers

Jonas S Heitmann, Martin Pfluegler, Gundram Jung, Helmut R Salih, Elpus

Affiliations

  1. Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
  2. DFG Cluster of Excellence 2180 "Image-Guided and Functional Instructed Tumor Therapy" (IFIT), University of Tübingen, 72076 Tübingen, Germany.
  3. Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, 72076 Tübingen, Germany.
  4. German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, 72076 Tübingen, Germany.

PMID: 33535627 PMCID: PMC7867165 DOI: 10.3390/cancers13030549

Abstract

Prostate carcinoma (PC) is the second most common cancer in men. When the disease becomes unresponsive to androgen deprivation therapy, the remaining treatment options are of limited benefit. Despite intense efforts, none of the T cell-based immunotherapeutic strategies that meanwhile have become a cornerstone for treatment of other malignancies is established in PC. This refers to immune checkpoint inhibition (CI), which generally reinforces T cell immunity as well as chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) that stimulate the T cell receptor/CD3-complex and mobilize T cells in a targeted manner. In general, compared to CAR-T cells, bsAb would have the advantage of being an "off the shelf" reagent associated with less preparative effort, but at present, despite enormous efforts, neither CAR-T cells nor bsAbs are successful in solid tumors. Here, we focus on the various bispecific constructs that are presently in development for treatment of PC, and discuss underlying concepts and the state of clinical evaluation as well as future perspectives.

Keywords: CRPC; bispecific antibody; prostate cancer

References

  1. Immunol Cell Biol. 2015 Mar;93(3):290-6 - PubMed
  2. J Immunol. 2018 Jan 15;200(2):459-468 - PubMed
  3. Clin Cancer Res. 1997 Jan;3(1):81-5 - PubMed
  4. Oncogene. 2000 Mar 2;19(10):1288-96 - PubMed
  5. J Clin Oncol. 2008 Jan 10;26(2):242-5 - PubMed
  6. J Hematol Oncol. 2015 Oct 08;8:111 - PubMed
  7. Nature. 1997 Feb 20;385(6618):729-33 - PubMed
  8. N Engl J Med. 2006 Sep 7;355(10):1018-28 - PubMed
  9. Immunity. 2016 May 17;44(5):973-88 - PubMed
  10. Blood. 2014 Jul 10;124(2):188-95 - PubMed
  11. Curr Opin Drug Discov Devel. 2008 Sep;11(5):675-87 - PubMed
  12. J Clin Oncol. 2006 Jul 1;24(19):3089-94 - PubMed
  13. Nat Biotechnol. 2015 Oct;33(10):1079-86 - PubMed
  14. Lancet Oncol. 2015 Feb;16(2):152-60 - PubMed
  15. Leukemia. 2016 Feb;30(2):484-91 - PubMed
  16. Cancer Metastasis Rev. 2005 Dec;24(4):521-37 - PubMed
  17. Leukemia. 2018 May;32(5):1239-1243 - PubMed
  18. Eur Urol. 2019 Mar;75(3):378-382 - PubMed
  19. J Immunol. 1986 Aug 1;137(3):819-25 - PubMed
  20. Curr Pharm Des. 2009;15(20):2319-35 - PubMed
  21. Prostate Cancer. 2015;2015:285193 - PubMed
  22. J Clin Oncol. 2020 Feb 10;38(5):395-405 - PubMed
  23. Nature. 1997 Feb 20;385(6618):733-6 - PubMed
  24. Blood. 2017 Feb 2;129(5):609-618 - PubMed
  25. Cancer. 2019 Dec 1;125(23):4172-4180 - PubMed
  26. J Hematol Oncol. 2017 Sep 20;10(1):155 - PubMed
  27. Nature. 2017 Jul 13;547(7662):217-221 - PubMed
  28. Prostate. 2008 Jun 1;68(8):830-8 - PubMed
  29. J Immunother Cancer. 2018 Jun 15;6(1):56 - PubMed
  30. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  31. J Clin Pharmacol. 2015 Mar;55 Suppl 3:S21-8 - PubMed
  32. Cancer. 2010 Feb 15;116(4 Suppl):1075-83 - PubMed
  33. Front Oncol. 2018 Jul 25;8:285 - PubMed
  34. Nature. 1992 Apr 16;356(6370):607-9 - PubMed
  35. Ann Oncol. 2018 Aug 1;29(8):1807-1813 - PubMed
  36. Oncoimmunology. 2018 Apr 18;7(8):e1450710 - PubMed
  37. Annu Rev Chem Biomol Eng. 2012;3:263-86 - PubMed
  38. Biochem J. 2012 Jul 1;445(1):135-44 - PubMed
  39. Cancer Res. 1997 Sep 1;57(17):3629-34 - PubMed
  40. J Mol Biol. 2001 Feb 2;305(5):989-1010 - PubMed
  41. Cancer Res. 2017 Oct 1;77(19):5384-5394 - PubMed
  42. Nat Rev Immunol. 2012 Apr 10;12(5):317-8 - PubMed
  43. EMBO Mol Med. 2021 Feb 5;13(2):e11902 - PubMed
  44. Nat Biotechnol. 1997 Feb;15(2):159-63 - PubMed
  45. Cancer Cell. 2017 Mar 13;31(3):383-395 - PubMed
  46. Protein Cell. 2018 Jan;9(1):15-32 - PubMed
  47. J Med Radiat Sci. 2017 Mar;64(1):52-60 - PubMed
  48. Science. 2013 Dec 20;342(6165):1432-3 - PubMed
  49. J Clin Oncol. 2005 Jul 20;23(21):4591-601 - PubMed
  50. Cancer Res. 1994 Apr 1;54(7):1807-11 - PubMed
  51. Mol Cancer Ther. 2016 Sep;15(9):2155-65 - PubMed
  52. Cancer Res. 1999 Jul 1;59(13):3192-8 - PubMed
  53. Cell. 2017 Feb 9;168(4):724-740 - PubMed
  54. Mol Ther. 2015 Apr;23(4):648-55 - PubMed
  55. Cancer Immunol Immunother. 2006 Dec;55(12):1524-33 - PubMed
  56. J Immunol. 2017 Nov 1;199(9):3348-3359 - PubMed
  57. Immunotherapy. 2021 Feb;13(2):125-141 - PubMed
  58. Blood. 2013 Jun 27;121(26):5154-7 - PubMed
  59. Urology. 2006 Jul;68(1):110-5 - PubMed
  60. Nat Biotechnol. 2005 Sep;23(9):1147-57 - PubMed
  61. Lancet. 2010 Oct 2;376(9747):1147-54 - PubMed
  62. Cancer Cell. 2017 Apr 10;31(4):501-515.e8 - PubMed
  63. Clin Pharmacol. 2013 Apr 12;5(Suppl 1):5-11 - PubMed
  64. J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S - PubMed
  65. Nature. 2019 Jan;565(7738):240-245 - PubMed
  66. Clin Colorectal Cancer. 2016 Dec;15(4):345-351 - PubMed
  67. Nat Rev Cancer. 2015 Jun;15(6):361-70 - PubMed
  68. J Immunol. 2012 Sep 15;189(6):3249-59 - PubMed
  69. BMJ Open. 2020 Oct 16;10(10):e039639 - PubMed
  70. Immunotargets Ther. 2017 Mar 20;6:11-16 - PubMed
  71. Int J Mol Sci. 2020 Jul 31;21(15): - PubMed
  72. Histopathology. 2007 Mar;50(4):472-83 - PubMed
  73. Mol Ther. 2018 Jul 5;26(7):1855-1866 - PubMed
  74. J Clin Oncol. 2017 Jan;35(1):40-47 - PubMed
  75. Mol Cancer Ther. 2018 Sep;17(9):1927-1940 - PubMed
  76. N Engl J Med. 2017 Oct 5;377(14):1345-1356 - PubMed
  77. Oncotarget. 2016 Nov 22;7(47):76902-76919 - PubMed
  78. Front Immunol. 2020 Jun 17;11:1109 - PubMed
  79. Eur Urol. 2016 Dec;70(6):926-937 - PubMed
  80. Cancer Res. 2001 Jun 1;61(11):4320-4 - PubMed
  81. JAMA Oncol. 2019 Apr 1;5(4):471-478 - PubMed
  82. Lancet Oncol. 2014 Jun;15(7):700-12 - PubMed
  83. J Immunother Cancer. 2020 May;8(1): - PubMed
  84. Clin Cancer Res. 2005 Apr 1;11(7):2591-6 - PubMed
  85. Clin Exp Immunol. 2011 Mar;163(3):324-32 - PubMed
  86. Rev Urol. 2004;6 Suppl 10:S13-8 - PubMed
  87. Science. 2018 Mar 23;359(6382):1344-1345 - PubMed
  88. Lancet Oncol. 2012 Oct;13(10):983-92 - PubMed
  89. Sci Transl Med. 2020 Jan 8;12(525): - PubMed
  90. Gut. 2001 Aug;49(2):236-40 - PubMed
  91. Cancer. 2019 Aug 1;125(15):2561-2569 - PubMed
  92. Cell. 1989 Mar 10;56(5):855-65 - PubMed
  93. Lancet Oncol. 2018 Jun;19(6):825-833 - PubMed
  94. N Engl J Med. 2010 Jul 29;363(5):411-22 - PubMed
  95. Annu Rev Immunol. 2000;18:767-811 - PubMed
  96. Invest New Drugs. 2019 Oct;37(5):810-817 - PubMed
  97. Cancer Res. 2013 Sep 15;73(18):5613-7 - PubMed
  98. N Engl J Med. 2012 Sep 27;367(13):1187-97 - PubMed
  99. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  100. Prostate. 2016 Oct;76(14):1257-70 - PubMed
  101. Int J Cancer. 2001 Jan 15;91(2):225-30 - PubMed
  102. Nature. 2007 Sep 27;449(7161):419-26 - PubMed
  103. Cancer Lett. 2009 May 18;277(2):126-32 - PubMed
  104. Lancet. 2019 May 4;393(10183):1819-1830 - PubMed
  105. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39 - PubMed
  106. MAbs. 2017 Feb/Mar;9(2):182-212 - PubMed
  107. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 - PubMed
  108. Mol Imaging Biol. 2016 Jun;18(3):411-9 - PubMed
  109. BJU Int. 2006 Jun;97(6):1202-7 - PubMed
  110. J Immunol. 1985 Dec;135(6):3669-73 - PubMed
  111. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4611-5 - PubMed
  112. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6803-8 - PubMed

Publication Types